DuoGel (IQP-0528) / Statera BioPharma, National Institute of Allergy and Infectious Diseases, Samjin Pharma - LARVOL DELTA

ART with or without the aid of chemo-mechanical agents: a systematic review. (PubMed, Clin Oral Investig) - "The use of chemo-mechanical agents for carious tissue removal in the ART may benefit patients with reduced pain/discomfort."

Clinical • Journal • Review • Dental Disorders • Pain

Approved HIV reverse transcriptase inhibitors in the past decade. (PubMed, Acta Pharm Sin B) - "Here, we provide a comprehensive review of RT inhibitors (tenofovir alafenamide, rilpivirine, doravirine, dapivirine, azvudine and elsulfavirine) approved in the past decade, regarding their drug discovery, pharmacology, and clinical efficacy in randomized controlled trials. Novel RT inhibitors such as islatravir, MK-8504, MK-8507, MK8583, IQP-0528, and MIV-150 will be also highlighted. Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability, longer elimination half-life, more favorable side-effect profiles, fewer drug-drug interactions, and higher activities against circulating drug-resistant strains."

Journal • Review • Human Immunodeficiency Virus • Immunology • Infectious Disease

Examining the Safety, Pharmacokinetics, and Pharmacodynamics of a Rectally Administered IQP-0528 Gel for HIV Pre-Exposure Prophylaxis: a First-in-Human Study. (PubMed, AIDS Res Hum Retroviruses) - "The IQP-0528 gel possesses desirable features for a topical microbicide including: local safety with no systemic absorption, delivery of locally high IQP-0528 concentrations, and significant reductions in ex vivo HIV infectivity. However, the gel is limited by its rapid clearance and inability to penetrate vaginal tissues following rectal dosing."

Clinical • Journal • P1 data • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

Cytocom Announces Acquisition of ImQuest Life Sciences (PRNewswire) - "Cytocom, Inc....today announced the acquisition of ImQuest Life Sciences, Inc., a research and development company focused specifically on cancer, inflammation and infectious disease treatments, including its subsidiaries in an all-stock transaction....'The acquisition by Cytocom aligns ImQuest with a company that shares our excitement for the promise of our preclinical CRO services and tools, as well as the potential for our portfolio of novel therapeutic agents in development for HIV...' said Dr. Buckheit."

M&A • Human Immunodeficiency Virus

[VIRTUAL] A PHASE I TRIAL OF A RECTALLY ADMINISTERED GEL FORMULATED WITH THE NNRTI IQP-0528 (CROI 2020) - "The offset of IQP-0528 accumulation by its short half-life in RT indicates that this gel may be better suited for episodic use. Furthermore, dual protection is not offered from single-compartment dosing."

P1 data